1,720,972 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
Significance of re-measurement of prostate specific antigen before prostate biopsy
No full text1988年8月～2002年2月に初回前立腺生検を行った患者のうち、生検の適応と決めてから3ヵ月以内に生検を実施した症例で、生検目的の入院時に再度の前立腺特異抗原(PSA)測定がなされていた344例中の288例について、2回のPSA測定値の比較、f/t比の比較を行った。288例中前立腺癌は93例であり、陰性例は195例で、2回のPSA測定間隔は1～90日(平均31.4日)で、全例で検討すると"decision"と"just before"は各平均13.0ng/mlと11.7ng/mlで"just berore"は有意に低値であった。癌、陰性例に分けて各"decision"と"just before"を比較すると、陰性例では有意に"just before"が低い傾向はあるが有意差はなく、癌陰性例を症状有無で分け検討すると、有症状症例で"decision"と"just before"は各平均11.2ng/mlと9.2ng/mlでPSA値低下が顕著であった。To examine the natural change of prostate-specific antigen (PSA), we compared two PSA values, the first value with which we decided to perform prostate biopsy and the value obtained by remeasurement just before biopsy. To exclude cases with extremely high PSA, we examined 288 cases in which PSA was less than 50 ng/ml for comparison. Of the 288 cases, 93 were diagnosed with prostate cancer (CaP). The interval between the two PSA measurements was 1-90 days (average of 31.4 days). The first and second values were an average of 13.0 and 11.7 ng/ml, respectively, and the second value was significantly lower than the first value. When we divided them into CaP cases and non-CaPthe two cases, a significant difference between PSA values was found only in the non-CaP cases. Moreover, in the non-CaP cases with some clinical symptoms, the difference in PSA was marked between the first and second values, which averaged 11.2 and 9.2 ng/ml, respectively. When we decide to perform a biopsy, we should recognize that PSA sometimes is lower on re-measurement. Particularly in symptomatic cases, it is worth re-measuring PSA, which may save unnecessary biopsies
Prognosis of prostate cancer with elevated prostatic acid phosphatase
Get PDF前立腺癌1029例を対象に初診時PAPが高値の症例をstage D0に分類し, この分類を採用した場合と採用しない場合の生存曲線を比較するとともに, あわせてPAS値と予後の関係を検討した.その結果, stage D0を採用しない場合には予後と良好な相関が認められたが, stage D0分類を採用した場合には予後との関連が明確ではなかった.PSA値の検討では, PSA値が高値な群ほど有意に予後が悪く, stage D1, 2を除いた症例(転移を認めない症例)のみでの検討でも, PSA高値な群ほど有意に予後が悪かった.以上より, PAP値は臨床的stagingに匹敵するような予後因子とはいえず, PSAの測定がルーチンとなった現在における有用性は低いものと思われたTo evaluate the significance of prostatic acid phosphatase (PAP), we analyzed 1, 029 prostate cancer patients who were treated at the Niigata Cancer Center. We classified clinically localized prostate cancer with elevated PAP as stage DO. When stage DO was not taken into acount, the 5-year cause-specific survival rate for stage A, B, C and D was 94.7, 97.9, 87.7 and 42.4%, respectively. Taking stage DO into account, the cause-specific survival curve for stage DO patients was similar to those for stage B, C patients. The 5-year cause-specific survival rate for stage DO was 92.2% considering above 3 ng/ml as elevated PAP. A significant correlation was found between PAP and cause-specific survival for all cases but no correlation was found for non-metastatic disease patients. The significance of PAP in the staging of prostate cancer is limited
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Chemo-endocrine therapy for newly diagnosed stage D2 prostate cancer
Get PDFステージD2前立腺癌新鮮例175例を対象に, 化学療法併用内分泌療法群38例(化療あり群), 内分泌療法単独群137例(化療なし群)に分け, その治療成績を比較検討した.尚, 化療あり群のレジメンは, VIPが34例, CDDP+IFMが2例, CBDCA+VPが1例, CDDP+MTXが1例であった.その結果, 1)全症例の5年生存率は34.8%, 疾患特異的5年生存率は41.7%で, うち化療なし群の疾患特異的5年生存率は34.8%であったのに対し, 化療あり群は61.6%と有意に良好であった.2)Coxの比例ハザードモデルを用いた多変量解析においては, 最も強い相関がみられたのは全生存においては治療開始年代であったが, 疾患特異的生存においては化学療法の有無が最も強い相関を示したWe evaluated 175 patients with newly diagnosed stage D2 prostate cancer who had been treated in our hospital between 1992 and 2003 to compare chemo-endocrine therapy with endocrine therapy alone. One hundred and thirty seven patients were treated with endocrine therapy alone. The other 38 patients received chemo-endocrine therapy, which included medical or surgical castration with/without antiandrogen plus VIP (Vincristine, Ifosfamide, Peplomycin) regimen or other cytotoxic agents. The patients treated with chemo-endocrine therapy had a significantly better prognosis than the patients treated with endocrine therapy alone (p<0.05), although treatment was not randomized. The cause-specific survival rates at 5 years for the chemo-endocrine therapy group and the endocrine therapy group were 61.6% and 34.8%, respectively. These data suggest that chemo-endocrine therapy is a potentially effective treatment for newly diagnosed stage D2 prostate cancer
- …
